ArticleNature biotechnology2003
A genetic approach to inactivating chemokine receptors using a modified viral protein.
Article in Nature biotechnology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection.Cell stem cell · 2024Article
- CXCR4 blockade induces atherosclerosis by affecting neutrophil function.Journal of molecular and cellular cardiology · 2014Article
- C-C chemokine receptor 5 on pulmonary mesenchymal cells promotes experimental metastasis via the induction of erythroid differentiation regulator 1.Molecular cancer research : MCR · 2014Article
- Selective targeting of proteins within secretory pathway for endoplasmic reticulum-associated degradation.The Journal of biological chemistry · 2012Article
- SDF-1α and CXCR4 as therapeutic targets in cardiovascular disease.American journal of cardiovascular disease · 2012Article
- Article
- FoxP3 interacts with linker histone H1.5 to modulate gene expression and program Treg cell activity.Genes and immunity · 2011Article
- The heptad repeat 2 domain is a major determinant for enhanced human immunodeficiency virus type 1 (HIV-1) fusion and pathogenicity of a highly pathogenic HIV-1 Env.Journal of virology · 2009Article
- Maraviroc in the treatment of HIV infection.Drug design, development and therapy · 2009Article
- TSLP is involved in expansion of early thymocyte progenitors.BMC immunology · 2007Article
- FoxP3 enhances HIV-1 gene expression by modulating NFkappaB occupancy at the long terminal repeat in human T cells.The Journal of biological chemistry · 2007Article
- Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Citron kinase, a RhoA effector, enhances HIV-1 virion production by modulating exocytosis.Traffic (Copenhagen, Denmark) · 2006Article
- Delayed functional maturation of natural regulatory T cells in the medulla of postnatal thymus: role of TSLP.BMC immunology · 2006Article
- Article
- HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector.AIDS research and therapy · 2005Article
- Galpha13 mediates a signal that is essential for proliferation and survival of thymocyte progenitors.The Journal of experimental medicine · 2004Article
- Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope.Virology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
We have developed a genetic system, called degrakine, that specifically and stably inactivates chemokine receptors (CKR) by redirecting the ability of the HIV-1 protein, Vpu, to degrade CD4 in the endoplasmic reticulum (ER) via the host proteasome machinery. To harness Vpu's proteolytic targeting capability to degrade new receptors, we fused a chemokine with the C terminal region of Vpu. The fusion protein, or degrakine, accumulates in the ER, trapping and functionally inactivating its target CKR. We have demonstrated that degrakines based on SDF-1 (CXCL12), MDC (CCL22) and RANTES (CCL5) specifically inactivate their respective receptor functions. Using a retroviral vector expressing the SDF-1 degrakine, we have established that CXCR4 is required for the homing of hematopoietic stem/progenitor cells (HSPC) to the bone marrow immediately after transplantation. Thus the degrakine provides an effective genetic tool to dissect receptor functions in a number of biological systems in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.